A breakthrough leukemia treatment, blinatumomab, researched by CU Cancer Center Member Lia Gore, MD, at Children’s Hospital Colorado, is revolutionizing pediatric cancer care. The immunotherapy boosts survival rates to 96%, significantly reducing long-term side effects compared to traditional chemotherapy.